> 数据图表如何了解3.1 创新药（H）： 26H1收入同比稳健增长，盈利再创新高2026-9-23.1 创新药（H）： 26H1收入同比稳健增长，盈利再创新高图表24：H股创新药公司经营数据简称市值（亿元）翰森制药石药集团中国生物制药信达生物科伦博泰生物康方生物三生制药先声药业再鼎医药康诺亚-B和黄医药基石药业-B科济药业-B和铂医药-B加科思-B德琪医药-B2,226.81,098.11,045.31,874.71,229.8878.3430.5290.2235.3234.5173.094.080.0135.952.126.2营业收入增速持续经营利润增速202522.6%-10.4%10.3%38.4%6.5%43.9%94.3%16.5%15.3%67.3%-13.0%-33.8%218.7%314.6%-65.6%14.6%2026H111.7%40.1%10.6%44.8%2.9%27.9%3.9%27.8%-4.9%23.7%0.2%314.8%21.5%20.9%1500.5%864.8%202527.1%-10.3%22.1%959.7%-43.2%-116.3%305.8%83.3%33.2%-1.4%1025.4%-379.1%87.7%3114.7%6.2%25.1%2026H135.8%139.2%1.4%50.2%367.3%25.6%-15.6%37.3%-8.7%1644.1%-97.5%6.6%11.5%-13.9%1118.1%383.3%26年净利润一致预期（亿元）61.5879.1046.5629.39-1.00-0.9326.1217.47-2.568.070.56-3.50-2.120.943.843.64资料来源：Wind、中邮证券研究所（市值和26年净利润一致预期截止26/08/28）请参阅附注免责声明19中邮证券健康医疗
